Postoperative stimulated thyroglobulin of less than 1? ng/mL as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation

Thyroid

Volumn 22, Issue 11, 2012, Pages 1140-1143

  Rosario, Pedro Weslley ^a,b   Mineiro Filho, Augusto Flávio Campos ^a   Prates, Brenda Sá Senna ^a   Silva, Lívia Cristina Oliveira ^a   Calsolari, Maria Regina ^b  

^a Instituto de Ensino e Pesquisa da Santa Casa de Belo Horizonte   (Brazil)

^b Endocrinology Service   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ABLATION THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHILD; FEMALE; FOLLOW UP; HUMAN; MALE; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; THYROID CANCER; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NECK; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RECURRENCE; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84869044653     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0190     Document Type: Article

References (18)

1. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
3. Rosario PW, Borges MA, Valadao MM, Vasconcelos FP, Rezende LL, Padrao EL, Barroso AL, Purisch S 2007 Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2cm? Thyroid 17:1225-1228.
4. Souza Rosário PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, Purisch S 2004 Post I-131 therapy scanning in patients with thyroid carcinoma metastases: An unnecessary cost or a relevant contribution? Clin Nucl Med 29:795-798. (Pubitemid 39557551)
5. Rosario PW, Borges MA, Fagundes TA, Franco AC, Purisch S 2005 Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol (Oxf). 62:121-125. (Pubitemid 40203904)
6. Rosário PW, Guimara es VC, Maia FF, Fagundes TA, Purisch S, Padrao EL, Rezende LL, Barroso AL 2005 Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope 115:264-267. (Pubitemid 40216700)
7. Rosario PW, Xavier AC, Calsolari MR 2011 Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21:49-53.
8. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S 2011 Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18:R29-R40.
9. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440-1445.
10. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5cm in diameter: study of 299 cases. J Clin Endocrinol Metab 89:3713-3720. (Pubitemid 39071462)
11. Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, Freeman JL, Walfish PG 2010 Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32: 689-698.
12. Rosario PW, Faria S, Bicalho L, Gatti Alves MF, Borges MAR, Purisch S, Padrao EL, Rezende LL, Barroso AL 2005 Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385-1389. (Pubitemid 41395927)
13. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501. (Pubitemid 34615228)
14. Schlumberger M, Pacini F 2006 Distant metastases. In: Schlumberger M, Pacini F (eds) Thyroid Tumors, 3rd edition. É ditions Nucle'on, Paris.
15. .Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M; THYRDIAG Working Group 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: A prospective study on 715 patients. J Clin Endocrinol Metab 96:1352-1359.
16. .Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G 2011 Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin J Clin Endocrinol Metab 96:1703-1709.
17. .Wong H, Wong KP, Yau T, Tang V, Leung R, Chiu J, Lang BH 2012 Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol 19:3479-3485.
18. .Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349